Harrow Share Price (NASDAQ: HROW)

$39.04

▲

0.05

(0.13%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Harrow Stock chart to analyse performance

Harrow stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$38.50
Today's High:$39.56
$39.04
1.38%
Downside
Day's Volatility :2.68%
Upside
1.31%
52 Weeks Low:$20.85
52 Weeks High:$59.23
$39.04
46.59%
Downside
52 Weeks Volatility :64.8%
Upside
34.09%

Harrow Stock Returns

Period	Harrow Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	30.12%	3.6%	0.0%
6 Months	52.2%	-7.7%	0.0%
1 Year	-1.56%	-12.6%	0.0%
3 Years	339.3%	10.2%	-4.1%

Harrow Inc Key Stats

Check Harrow key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$38.99
Open	$39.42
Today's High	$39.56
Today's Low	$38.5
Market Capitalization	$1.4B
Today's Volume	$348.8K
52 Week High	$59.23
52 Week Low	$20.85
Revenue TTM	$227.7M
EBITDA	$31.1M
Earnings Per Share (EPS)	$-0.28
Profit Margin	-4.49%
Quarterly Earnings Growth YOY	-0.64%
Return On Equity TTM	-19.03%

Stock Returns calculator for Harrow Stock including INR - Dollar returns

The Harrow stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Harrow investment value today

Current value as on today

₹1,03,795

Returns

₹3,795

(+3.8%)

Returns from Harrow Stock

₹1,489 (-1.49%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Harrow Stock

125%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Harrow Stock from India on INDmoney has increased by 125% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Harrow Inc

Name
Holdings %
Name
Holdings %
Opaleye Management Inc
10.64%
BlackRock Inc
7.01%
Private Capital Management, LLC
5.30%
Vanguard Group Inc
5.09%
BRAIDWELL LP
2.38%
State Street Corp
2.14%

Analyst Recommendation on Harrow Stock

Rating

Trend

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Harrow(by analysts ranked 0 to 5 stars)

Harrow Share Price Target

What analysts predicted

Upside of 53.94%

Target:

$60.10

Current:

$39.04

Harrow share price target is $60.10, a slight Upside of 53.94% compared to current price of $39.04 as per analysts' prediction.

Harrow Stock Insights

Price Movement
In the last 1 month, HROW stock has moved up by 22.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 47.83M → 63.74M (in $), with an average increase of 25.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -17.78M → 4.99M (in $), with an average increase of 456.0% per quarter
HROW vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 13.5%
Price to Sales
ForHROW every $1 of sales, investors are willing to pay $6.2, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Harrow Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$51.2M	↑ 23.67%
Net Income	$168.0K	↓ 98.85%
Net Profit Margin	0.33%	↓ 35.02%

	FY20	Y/Y Change
Revenue	$48.9M	↓ 4.48%
Net Income	$-3.4M	↓ 2098.21%
Net Profit Margin	-6.87%	↓ 7.2%

	FY21	Y/Y Change
Revenue	$72.5M	↑ 48.3%
Net Income	$-18.0M	↑ 436.4%
Net Profit Margin	-24.85%	↓ 17.98%

	FY22	Y/Y Change
Revenue	$88.6M	↑ 22.24%
Net Income	$-14.1M	↓ 21.77%
Net Profit Margin	-15.9%	↑ 8.95%

	FY23	Y/Y Change
Revenue	$130.2M	↑ 46.95%
Net Income	$-24.4M	↑ 73.3%
Net Profit Margin	-18.75%	↓ 2.85%

	FY24	Y/Y Change
Revenue	$199.6M	↑ 53.32%
Net Income	$-17.5M	↓ 28.39%
Net Profit Margin	-8.76%	↑ 9.99%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$34.6M	↓ 4.86%
Net Income	$-13.6M	↑ 48.28%
Net Profit Margin	-39.22%	↓ 14.06%

	Q2 FY24	Q/Q Change
Revenue	$48.9M	↑ 41.5%
Net Income	$-6.5M	↓ 52.28%
Net Profit Margin	-13.23%	↑ 25.99%

	Q3 FY24	Q/Q Change
Revenue	$49.3M	↑ 0.65%
Net Income	$-4.2M	↓ 34.81%
Net Profit Margin	-8.57%	↑ 4.66%

	Q4 FY24	Q/Q Change
Revenue	$66.8M	↑ 35.68%
Net Income	$6.8M	↓ 260.59%
Net Profit Margin	10.14%	↑ 18.71%

	Q1 FY25	Q/Q Change
Revenue	$47.8M	↓ 28.43%
Net Income	$-17.8M	↓ 362.36%
Net Profit Margin	-37.17%	↓ 47.31%

	Q2 FY25	Q/Q Change
Revenue	$63.7M	↑ 33.27%
Net Income	$5.0M	↓ 128.09%
Net Profit Margin	7.84%	↑ 45.01%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$34.4M	↑ 38.49%

	FY20	Y/Y Change
Profit	$34.4M	↓ 0.02%

	FY21	Y/Y Change
Profit	$54.3M	↑ 57.7%

	FY22	Y/Y Change
Profit	$63.2M	↑ 16.49%

	FY23	Y/Y Change
Profit	$90.6M	↑ 43.25%

	FY24	Y/Y Change
Profit	$150.4M	↑ 66.06%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$24.0M	↓ 4.07%

	Q2 FY24	Q/Q Change
Profit	$36.4M	↑ 51.45%

	Q3 FY24	Q/Q Change
Profit	$37.2M	↑ 2.3%

	Q4 FY24	Q/Q Change
Profit	$52.7M	↑ 41.51%

	Q1 FY25	Q/Q Change
Profit	$32.3M	↓ 38.69%

	Q2 FY25	Q/Q Change
Profit	$47.5M	↑ 47.06%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$950.0K	↑ 38.28%
Investing Cash Flow	$-1.8M	↓ 16.64%
Financing Cash Flow	$-1.0M	↓ 124.35%

	FY20	Y/Y Change
Operating Cash Flow	$-1.1M	↓ 215.79%
Investing Cash Flow	$-981.0K	↓ 46.48%
Financing Cash Flow	$1.4M	↓ 242.45%

	FY21	Y/Y Change
Operating Cash Flow	$5.1M	↓ 562.0%
Investing Cash Flow	$-18.7M	↑ 1804.79%
Financing Cash Flow	$51.5M	↑ 3491.77%

	FY22	Y/Y Change
Operating Cash Flow	$1.7M	↓ 66.45%
Investing Cash Flow	$-1.7M	↓ 90.67%
Financing Cash Flow	$54.1M	↑ 5.19%

	FY23	Y/Y Change
Operating Cash Flow	$3.8M	↑ 125.22%
Investing Cash Flow	$-152.6M	↑ 8652.32%
Financing Cash Flow	$126.5M	↑ 133.7%

	FY24	Y/Y Change
Operating Cash Flow	$-22.2M	↓ 678.18%
Investing Cash Flow	$-33.2M	↓ 78.26%
Financing Cash Flow	$28.5M	↓ 77.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-4.6M	↓ 153.22%
Investing Cash Flow	$-110.0K	↓ 45.81%
Financing Cash Flow	$-809.0K	↑ 4394.44%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-2.7M	↓ 40.67%
Investing Cash Flow	$5.1M	↓ 4739.09%
Financing Cash Flow	$73.0K	↓ 109.02%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$3.0M	↓ 207.47%
Investing Cash Flow	$-597.0K	↓ 111.7%
Financing Cash Flow	$-721.0K	↓ 1087.67%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-17.8M	↓ 702.47%
Investing Cash Flow	$-37.6M	↑ 6191.46%
Financing Cash Flow	$30.0M	↓ 4258.81%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$19.7M	↓ 210.62%
Investing Cash Flow	$-212.0K	↓ 99.44%
Financing Cash Flow	$23.0K	↓ 99.92%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-803.0K	↓ 104.08%
Investing Cash Flow	$-293.0K	↑ 38.21%
Financing Cash Flow	$-12.7M	↓ 55173.91%

Harrow Technicals Summary

Sell

Neutral

Buy

Harrow is currently in a neutral trading position according to technical analysis indicators.

Harrow Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Harrow Inc	24.91%	52.2%	-1.56%	339.3%	362.75%
Haleon Plc Spon Ads	1.5%	-7.33%	-3.49%	69.05%	32.32%
United Therapeutics Corporation	3.57%	-1.69%	-13.51%	34.83%	71.41%
Zoetis Inc.	6.13%	-8.28%	-14.8%	-1.88%	-3.48%
Neurocrine Biosciences Inc.	8.29%	21.94%	11.59%	32.16%	20.59%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Harrow Inc	NA	NA	NA	0.74	-0.19	0.03	NA	1.35
Haleon Plc Spon Ads	21.53	21.53	3.14	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.9	11.9	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Harrow Inc	Buy	$1.4B	362.75%	NA	-4.49%
Haleon Plc Spon Ads	Buy	$43.4B	32.32%	21.53	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.41%	11.9	40.36%
Zoetis Inc.	Buy	$69.3B	-3.48%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.59%	41.3	13.88%

About Harrow Inc

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Organization	Harrow
Employees	382
CEO	Mr. John P. Saharek MBA
Industry	Health Technology

Key Management of Harrow Inc

Name	Title
Mr. Mark L. Baum J.D.	CEO & Chairman of the Board
Mr. John P. Saharek MBA	President & CEO of Harrow's ImprimisRx Division
Dr. Amir H. Shojaei Ph.D., Pharm.D.	Chief Scientific Officer
Mr. Michael D. Biega	Vice President of Investor Relations & Communications
Mr. Brett A. Burrell	Vice President of Legal & Compliance
Ms. Kim Barratt	Chief Talent Officer
Dr. Mark A. Mannebach Ph.D., R.Ph.	Head of Regulatory Affairs & Pharmacovigilance
Mr. Greg DiPasquale	Senior VP & Head of Commercial
Dr. Prashanth S. Annavajjhala	Chief of Staff

Important FAQs about investing in HROW Stock from India :

What is Harrow share price today?

Harrow share price today is $39.04 as on August 30, 2025 at 1:29 am IST at the close of the market. Harrow share today touched a day high of $39.56 and a low of $38.50.

What is the 52 week high and 52 week low for Harrow share?

Harrow share touched a 52 week high of $59.23 and a 52 week low of $20.85. Harrow stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $39.04, lower by 34.09% versus the 52 week high.

How to invest in Harrow Stock (HROW) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Harrow on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Harrow Shares that will get you 0.0384 shares as per Harrow share price of $39.04 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Harrow Stock (HROW) from India?

Indian investors can start investing in Harrow (HROW) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Harrow stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Harrow share’s latest price of $39.04 as on August 30, 2025 at 1:29 am IST, you will get 0.2561 shares of Harrow. Learn more about fractional shares .

What are the returns that Harrow has given to Indian investors in the last 5 years?

Harrow stock has given 362.75% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?